Impact of Short-course Colchicine Versus Placebo After Pulmonary Vein Isolation (IMPROVE-PVI Pilot)
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Recurrence is a common problem after catheter ablation for atrial fibrillation, affecting at
least one out of three patients. Inflammation due to the procedure may contribute to
pulmonary vein reconnection and, thus, failure of catheter ablation.
This pilot study will assess whether a randomized, placebo-controlled, double-blind trial
investigating a 10-day treatment with colchicine, a potent anti-inflammatory drug, to improve
patient relevant outcomes after catheter ablation for atrial fibrillation is feasible.